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INTRODUCTION
“This Centre is forging global partnerships to relieve the human suffering from cancer.”
The words of former US Senator George Mitchell, captured on a giant 10-meter high banner, greet every visitor to the
Centre for Cancer Research and Cell Biology (CCRCB) at Queen’s University Belfast (QUB) in Northern Ireland (NI),
reflecting the aspiration to match local ambition with global collaboration to achieve better outcomes for patients with can-
cer. The opening of the CCRCB by Senator Mitchell represented an important step in a capacity-building initiative that
commenced in the mid-1990s to address the fragmented and uncoordinated nature of cancer care and research in NI.
THE CHALLENGE: FRAGMENTED CANCER SERVICES AND POOR CANCER OUTCOMES
The publication of the Campbell Report in 19961 highlighted significant deficiencies in cancer services in NI. For exam-
ple, among patients with breast cancer, there was wide variation in treatment provision across the province. Although
some patients received quality care from specialist breast cancer teams, audit data indicated that 64% of surgeons in NI
had performed <10 breast cancer surgeries per year.1 Similar issues were identified for several other malignancies, such
that NI had the poorest cancer outcomes in the United Kingdom for the majority of cancers.2 However, as well as high-
lighting the problems that an uncoordinated cancer care system with a limited and underresourced cancer research activity
can pose, the Campbell Report1 also provided a blueprint for change, recommending the development and implementa-
tion of a population-level cancer plan that emphasized the need for a comprehensive and coordinated research-enabled
partnership approach to achieve improved outcomes for patients with cancer. Key principles of this strategy included: 1)
the consolidation and expansion of cancer services within an overarching cancer center framework; 2) the production of
comprehensive incidence and mortality data through a research-active national cancer registry; 3) the introduction of ro-
bust cancer screening services; and 4) the development of an expanded research capacity to enable discovery science to be
translated into clinical applications.
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RESPONDING TO THE CHALLENGE:
EXEMPLARS OF AN INTEGRATED
PARTNERSHIP-ENABLED APPROACH TO
IMPROVING CANCER CARE AND
RESEARCH
The question remains: were the ambitions of the Camp-
bell Report rewarded with measurable outputs of success?
In the clinical setting, the introduction of a province-wide
2-view mammography screening program (unlike the
single-view approach that was used initially in the rest of
the United Kingdom) raised attendance levels at breast
screening clinics from just under 30% to nearly 80% and
resulted in better detection of small invasive cancers.
Breast cancer services were reorganized to ensure patients
were seen by specialist teams with dedicated breast cancer
surgeons rather than general surgeons with low-volume
activity as had been the case previously. Enhanced screen-
ing, in combination with this consolidation of breast can-
cer services, yielded a decrease in breast cancer mortality
of 29.6% by 2006.3 Continuing this upward trend, by
2013, survival in NI for breast cancer was the highest in
the United Kingdom (81.9%) compared with England
(79.3%), Scotland (78.5%), andWales (78.2%).4
From a public health perspective, the ability to cap-
ture NI population-level data through the precise develop-
ment and interrogation of comprehensive population-
based cohorts, particularly in patients with cancers of the
gastrointestinal tract, has yielded findings that not only
increased our understanding of disease etiology but also
delivered population-relevant, practice-changing clinical
interventions. The NI Barrett Esophagus Register5 is to
our knowledge one of the largest population-based regis-
tries of Barrett esophagus (BE) in the world (>13,000),
and includes every patient in NI diagnosed between 1993
and 2010. The precise evaluation of this unrivalled
resource has revealed that progression from BE to esopha-
geal cancer is lower than was previously suspected,6 thus
questioning the cost-effectiveness of a BE surveillance pro-
gram. Research on the NI BE cohort has also revealed that
smoking leads to a 2-fold increase in the risk of esophageal
cancer,7 emphasizing the need for smoking cessation strat-
egies for patients with BE. The availability of population-
based cohorts for colorectal adenoma/colorectal cancer
(CRC) has also contributed to research with potentially
practice-changing clinical implications.8 Pharmacoepide-
miological studies of general practitioner databases have
shown that bisphosphonates (which are increasingly used
to treat osteoporosis but are potentially associated with a
higher risk of esophagitis) do not lead to an increased risk
of esophageal cancer,9 thus supporting their continued use
for the treatment of a common complication, particularly
in postmenopausal women. Similar investigations of the
use of statins after diagnosis have indicated that these drugs
may increase overall survival in patients with CRC.10
From the perspective of translational research, bio-
marker and drug discovery research has underpinned the
development of new prognostic/predictive tests and the
identification of novel agents with therapeutic potential.
For example, in CRC, gene expression profiling in >500
patients with AJCC TNM stage II disease (using proprie-
tary CRC disease-specific array technology developed in
collaboration with Almac Diagnostics [Craigavon, UK])
has led to the identification of a 634-gene signature
(ColDx). Initial validation of this signature in primary
tumors from 215 patients with AJCCTNM stage II disease
from 12 centers as part of an international clinical trial
yielded positive results that outperformed conventional
clinicopathological risk factors (hazard ratio of 2.53 [95%
confidence interval,1.54-4.15] [P5 .0003] for 5-year
recurrence-free survival and 2.21 [P5 .008] for cancer-
related death).11 This research has resulted in the develop-
ment, commercialization, and licensing of a molecular test
(GeneFx Colon; Helomics, Pittsburgh, Pa) with significant
prognostic potential.12
These exemplars highlight the relevance of a cross-
sectoral, patient-focused partnership (involving clinicians,
allied health care professionals, pathologists, patient advo-
cates, basic and translational scientists, bioinformaticians,
biostatisticians, and the biotech/biopharma industry) to
improve patient outcomes. The success of this partnership
was recognized in 2012, when Queen Elizabeth II pre-
sented her Queen’s Diamond Jubilee Award to the Vice
Chancellor and the Dean of Medicine of QUB, thus val-
orizing the impact of the university-led comprehensive
cancer program on patient care.13
COMPREHENSIVE CANCER CARE IN NI:
PARTNERSHIP AND INTEGRATION
The development of an integrated cancer plan, aggregat-
ing services and expertise around a single comprehensive
cancer center,1 and the implementation of a collaborative
translational research strategy that values innovation and
cross-sectoral partnership have, as outlined above, under-
pinned a significant change in the last 20 years. The cross-
sectoral embrace of the program is key to its ongoing
activities, connecting patient research advocacy, academic
endeavor, industry rigor, and clinical excellence in an
added-value partnership (underpinned by support from
government agencies, industry and academic leaders,
National Health Service Hospital Trusts, research
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councils, and charities) that drives a translational contin-
uum from discovery science to clinical application.
Herein, we detail the collaborative activities of the key
stakeholders that catalyzed and delivered a truly transfor-
mative change for patients with cancer in NI.
Cancer at the Population Level: The Northern
Ireland Cancer Registry
Having a functional, research-enabled cancer registry that
captures population-level data has played a key role in the
development of the comprehensive cancer program in NI.
The Northern Ireland Cancer Registry (NICR) (www.
qub.ac.uk/research-centers/nicr/) was founded in 1994
and demonstrates the value of an intersectoral partnership
located within the Centre for Public Health at QUB, but
funded through NI’s Public Health Agency, a government
body. Capturing cancer incidence, prevalence, and sur-
vival data at an entire population level is a vital resource,
underpinning not only cancer research efforts but also
service planning and cancer policy initiatives. Unlike
many other European registries in which data coverage
can be suboptimal (varying from 17%-100%, with a Eu-
ropean average of 50%),14 data coverage in the NICR is
extremely high, with a registry completeness of 100%.15
In 1995, the NICR established what to our knowledge is
the first entirely electronic total population-based cancer
registry in the world. The NICR embraces the outreach
ethos that Senator Mitchell highlighted, contributing sig-
nificantly to European and international initiatives
including EUROCARE (a collaborative research project
on cancer survivorship in Europe), the International Can-
cer Benchmarking Partnership (ICBP), and RARECARE-
Net (an information network on rare cancers in
Europe).3,4,16 An added-value aspect of the NICR is its
ability to collect data across the entire cancer journey
because health and social care in NI are linked at a service
delivery level, thus increasing the potential impact for
both patients with cancer and cancer survivors. The
NICR is increasingly patient-focused and has recently
commenced a £2.1-million ($3.23-million) Movember-
funded program to evaluate patient-reported outcomes in
individuals with prostate cancer.
Molecular Pathology: The Foundation of
Innovation
The establishment of the Northern Ireland Molecular Pa-
thology Laboratory17 and the Northern Ireland Biobank
(www.nibiobank.org) have been key infrastructural com-
ponents of the translational research approach, providing
a tripartite linkage between QUB, the hospital trusts, and
the bioindustry sector. Collecting high-quality, clinically
annotated biospecimens, both for specific targeted cohorts
and on a population basis through the Northern Ireland
Biobank, has provided additional impetus to the transla-
tional research effort, delivering a rich resource with
which to maximize the clinical impact of discovery science
in molecular diagnostics, molecular therapeutics, and mo-
lecular cancer epidemiology.
Molecular pathology is a key enabler of the precision
cancer medicine revolution, accelerating the introduction
of new therapies through the discovery, validation, and
clinical application of biomarkers for patient stratification
and the evaluation of disease response. We have developed
a hybrid molecular pathology model, moving away from
the traditional division between diagnostics and transla-
tional research. In this model,18 we apply the same analyt-
ical, quality-control, and organizational rigor to research
discovery and its translation as we do to pathology test val-
idation and its clinical application. The capability to per-
form both diagnostic and research functions is housed
within a single “hybrid” laboratory infrastructure, with
appropriate laboratory accreditation, thus ensuring the ro-
bust delivery of both the diagnostic requirements and the
research translation activities of the program.
Within this integrated environment, we have also
embedded digital pathology and automated quantitative
imaging of tissue biomarkers,19 providing a platform for
accelerated discovery, validation, and translation in
patients with solid tumors. To realize the value of the
comprehensive “omic” interrogation of cancer biospeci-
mens, we developed a novel translational platform, PICan
(Pathology Integromics in Cancer) (Fig. 1),20 that inte-
grates all laboratory data (traditional, molecular, and digi-
tal pathology) with relevant clinical information, thus
maximizing our ability to discover new biomarkers/thera-
peutic targets. PICan’s integromics framework was tested
and valorized in a study of a 288 tissue microarray cores
from a cohort of patients with breast cancer, incorporating
image-related information including p53 immunohisto-
chemistry and tissue pathology, mutational analysis, next-
generation sequencing, and unsupervised clustering of
gene expression profiling, in combination with clinical
data to comprehensively probe the involvement of p53 in
breast cancer.20 PICan’s browser-based approach allows
for data analysis and interpretation and digital image
assessment to be achieved seamlessly, facilitating the
incorporation of multiple high-dimensional data into a
single searchable interface. The translational bioinfor-
matics team continues to build on this unique platform
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for internal tissue biomarker discovery and validation of
multiplex genomic signatures.
Moving forward, a QUB-led collaborative approach
with centers at the University of Southampton, University
College London, University of Manchester, University of
Newcastle, and University of Leicester that was recently
supported through 1 of 5 Cancer Research UK (CRUK)
Centres Network Accelerator Awards21 will allow this
integrated digital and molecular pathology model to be
standardized and adopted at a UK level.
Bringing Precision Medicine to the Clinic: The NI
Cancer Trials Centre and the Experimental
Cancer Medicine Centre
In 1999, a historic agreement was signed between the US
National Cancer Institute (NCI) and the departments of
health in both the Republic of Ireland and NI. The NCI-
Ireland-Northern IrelandMemorandum ofUnderstanding
underpinned the development of appropriate infrastruc-
ture in cancer epidemiology, cancer care, and cancer
research and education on the island of Ireland22 and its
outputs and legacy are the subject of a separate publication
(unpublished data). From the perspective of clinical cancer
research and cancer treatment, one of the first key out-
comes from this agreement was the establishment of a ro-
bust cancer clinical trials infrastructure through the
creation of the Northern Ireland Cancer Clinical Trials
Unit (now known as the Northern Ireland Cancer Trials
Centre). Since its establishment in early 2000, the North-
ern Ireland Cancer Trials Centre has significantly enhanced
participation in cancer clinical trials in Northern Ireland,
such that in the period between April 2013 and March
2014, a total of 1665 patients in Northern Ireland were
recruited to cancer clinical trials and related translational
Figure 1. The PICan (Pathology Integromics in Cancer Platform) translational platform.
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studies, a rate that is nearly twice the recruitment target of
850 patients (10% of the incident cancers in NI).23
This enhanced cancer clinical trial activity, under-
pinned by patient-focused discovery research and its
translation, led to the subsequent designation of the
CCRCB as a CRUK center (one of the first to be estab-
lished in the United Kingdom) in 2009 and a Department
of Health/CRUK Experimental Cancer Medicine Centre
(ECMC) in 2007. Focused on driving early-phase clinical
trials, the ECMC provides the perfect conduit for translat-
ing discovery science conducted within the research pro-
gram into new treatments for patients with cancer.
A key exemplar of this approach has resulted from a
discovery joint research program between QUB, Almac
Discovery, and Almac Diagnostics. Discovery research
revealed that the endogenous protein FKBPL (FK506
binding-like) has significant antiangiogenic properties
and is mediated through a CD44-dependent mecha-
nism.24,25 In collaboration with Almac Discovery, a
23-amino acid linear peptide that represents the active do-
main of FKBPL has been developed (ALM201). QUB is
now leading a national first-in-human phase 1 clinical
trial of this novel antiangiogenic peptide, ALM201,26 for
the treatment of platinum-resistant ovarian cancer
(EudraCT number: 2014-001175-31). This trial is now
actively recruiting patients across 3 ECMC locations in
the United Kingdom and will be biomarker-driven, using
a novel “angiogenic (AADX) signature” developed by
Almac Diagnostics and Edinburgh University to select
patients for the expansion phase of the trial.
In patients with CRC, research within the center con-
cerning drug-resistant signaling pathways implicated acti-
vation of c-MET as a key mediator of resistance to MEK
inhibition in patients with KRAS-mutant CRC,27 provid-
ing the rationale for a successful e6-million (approximately
$6.65 million) European Commission Framework
VII-funded bid for the CCRCB to lead a pan-European
translational clinical trial program with 13 partners from 7
European countries (MErCuRIC trial) (mercuric.eu/). The
novel therapeutic strategy of the MErCuRIC trial investi-
gates the combination of a MET and a MEK inhibitor to
combat metastasis, improve survival, and potentially de-
velop a new clinical intervention approach in patients with
this poor-prognosis subtype of CRC.
In patients with prostate cancer, QUB, in partnership
with the University of Manchester, has been awarded a £5-
million (approximately $7.8 million) program to establish
FASTMAN (BelFAST MANchester), an International
Movember Centre of Excellence in Prostate Cancer
Research28 to address the issue of disease recurrence and the
use of advanced radiotherapy and DNA damage-inducing
treatments in this disease. All these examples emphasize how
complimentary partnerships with academia and/or bioindus-
try are driving our precision medicine pipeline, and deliver-
ing novel and informed opportunities to benefit patients.
Crossing the Rubicon: Bridging the
Academia-Industry Divide
The significant resources invested by the pharmaceutical
industry to create “in-house” oncology research and devel-
opment capacity has yielded limited success rates for new
drug approvals, and therapeutic improvements that can
often only be considered as marginal.29,30 Within the
CCRCB, our investigators have been quick to adopt a
team science approach, but also to realize that team sci-
ence is not the sole preserve of academia and also should
straddle the academia-industry intersect for mutual
advantage and benefit to patients. In pooling resources
and expertise, we have promoted the belief that we derisk
biomarker and drug discovery/development programs,
allowing for the delivery of transformative solutions that
will improve patient outcomes. Assets such as the antian-
giogenic peptide ALM20126 and the GeneFX Colon
prognostic/predictive test12 stemming from our collabo-
rative pipeline as described above are now beginning to
demonstrate the validity and merits of such an approach.
CCRCB-Almac: A Mutually Productive
Academia-Industry Partnership
Recognizing the need to bridge the divide outlined
above,31 the CCRCB has promoted increased engage-
ment between academia and industry. Almac is one of
NI’s leading indigenous companies, operating in the
pharmaceutical and biotechnology sectors and employing
>3500 employees worldwide. Within the Almac Group,
Almac Diagnostics specializes in biomarker discovery and
development. It has historical linkages with QUB, spin-
ning out from the CCRCB in the early 2000s. The recent
collaborative partnership, in operation since 2010, has
been extremely productive, delivering a series of high-
impact publications11,32,33 and several validated clinical
tests, as well as licensing and collaborative agreements
with global biotechnology/biopharmaceutical companies.
For example, discovery DNA microarray analysis of the
Fanconi anemia/BRCA DNA damage response (DDR)
pathway identified a 44-gene expression-based DDR defi-
ciency signature.32 Evaluation of this 44-gene signature in
3 independent data sets from 203 patients with breast can-
cer highlighted the ability of this biology to predict response
to DNA-damaging chemotherapy, leading to the
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development of a formalin-fixed paraffin-embedded tissue
assay that was validated as a predictor of response in the
neoadjuvant setting and recurrence-free survival in the adju-
vant setting after anthracycline/cyclophosphamide-based
therapy.32
CCRCB researchers, in collaboration with Almac
Diagnostics, also have identified the potential for this bio-
marker to be relevant in patients with CRC, and this work
has led to the CCRCB becoming a significant partner in a
£5-million (approximately $7.8 million) University of
Oxford-led Medical Research Council-CRUK stratified
medicine program in CRC (S-CORT [Stratification in
COloRecTal cancer]),34 which brings together all the
major UK centers in CRC research in a national collabo-
rative partnership with bioindustry and patient advocacy
groups. S-CORT aims to develop novel validated bio-
marker tests to stratify patients for more effective
chemotherapy-based, radiotherapy-based, or surgical or
novel biological therapeutic interventions.35
Key joint academic industry appointments at the
professorial level have helped to embed the QUB-Almac
partnership approach for mutual benefit. We have nur-
tured this close relationship, creating a “spin-in” bio-
marker and drug discovery research hub, with >25
research scientists from Almac currently embedded within
the CCRCB, operating in close proximity to the academic
research programs. There have been tangible benefits to
QUB, not least the adoption of an industry rigor to our
core operation and research practice, together with an
appreciably greater entrepreneurial culture permeating
across the scientific and clinical staff. The physical integra-
tion of the collaborating research structures with their
complementary skill sets has led to a productive accelera-
tion of asset delivery within the biomarker and drug devel-
opment pipelines as outlined above, and the industrial
partner has recognized the value of direct access to the
clinical expertise of the university/hospital to inform clini-
cal development while exploiting the wider biomedical
and medical expertise to appraise other potential exploit-
able medical indications for their products.
Embedding National and International Joint
Academia-Industry Partnerships
A crucial partner in enabling our precision medicine pro-
gram has been the local government development agency,
Invest Northern Ireland, which has recognized the impor-
tance of academic-industrial collaboration in expanding
the life science sector and directly contributing to the
growth of the regional knowledge-based economy. The
success of the CCRCB-Almac partnership model has been
adapted further and supported to help embed other joint
academia-industry activities within the CCRCB. Such
examples follow below.
PathXL
PathXL (www.pathxl.com) is a digital pathology software
company that spun out of the CCRCB and has become a
global leader in the provision of innovative digital pathol-
ogy solutions for biomarker/drug discovery research and
clinical applications. The company, in partnership with
the CCRCB, has pioneered a novel software algorithm
(TissueMark) for automated tumor recognition and
quantitative analysis for nucleic acid extraction and mo-
lecular diagnostics in solid tumors.36 TissueMark was
tested and validated for its ability to provide automated
tumor annotation and measurement of the percentage of
tumor nuclei in 245 hematoxylin and eosin-stained slides
from patients with non-small cell lung cancer. The auto-
mated approach demonstrated strong concordance with
manually drawn boundaries and automated analysis of
cell counts for percentage tumor measurements by Tissue-
Mark demonstrated reduced variability and significant
correlation (P<.001) with benchmark tumor cell
counts.36 This technology is now being applied across
lung, colon, breast, and prostate cancer, thereby facilitat-
ing tissue-based molecular assays including next-
generation sequencing. These studies have demonstrated
that robust image analysis technology can facilitate the
automated quantitative analysis of tissue samples for mo-
lecular profiling, bridging the gap between traditional an-
atomical pathology and molecular diagnostics and
providing the appropriate quality for application in preci-
sion medicine.
CV6 Therapeutics
Attracting international bioindustry into the program,
based on the academia-industry partnership model
described above, also has been successful. CV6 Therapeu-
tics has relocated from the University of Southern Califor-
nia and is now embedded within the CCRCB.37
Targeting a process such as thymidylate biosynthesis and
the enzyme thymidylate synthase have been critical com-
ponents of cancer treatment, with fluoropyrimidines such
as 5-fluorouracil and antifolates such as methotrexate
underpinning therapeutic intervention in many solid
tumors and hematological malignancies. Researchers at
CV6 Therapeutics have characterized resistance mecha-
nisms within the thymidylate biosynthesis pathway38 and
are using this knowledge to drive the development of new
innovative therapeutic approaches that will have relevance
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and clinical applicability for many cancers. Complement-
ing existing research in drug resistance mechanisms
(particularly in CRC) by CCRCB researchers,27,39-41 this
partnership has significant potential to deliver new drug
combinations and novel approaches with therapeutic
potential.
Overall, our partnership model has proven attractive
to the biotechnology and industry sectors, allowing dis-
tinct but complementary skills to be brought together in
an academic environment that favors innovation, with the
ability to unlock new collaborative funding schemes at
local, national, and international levels. The model also
enhances the opportunities for testing potential industry
assets in appropriate clinical settings. Similar cross-
sectoral approaches are being developed in this cancer
drug discovery space between the University of Manches-
ter, GlaxoSmithKline, and Cancer Research Technology,
with a particular emphasis on epigenetic targeting in can-
cer,42 whereas Pfizer’s Centers for Therapeutic Innovation
are strategically placed in biomedical research hubs and
aligned with academic centers in Boston, New York, San
Diego, and San Francisco and have recently partnered
with the National Institutes of Health’s National Center
for Advancing Translational Sciences.43
Patient-Focused Research: The Northern Ireland
Cancer Research Consumer Forum
The patient voice is a key supporter of an evolving preci-
sion cancer medicine partnership to deliver personalized
cancer care. The Northern Ireland Cancer Research Con-
sumer Forum (NICRCF)23 engages at the earliest stages
of the translational process, being involved in research
grant preparation (the NICRCF is a funded partner in
both the MErCuRIC and S-CORT programs) and sub-
mission, clinical trial design, and patient-reported out-
comes research, thus providing a distinctive and extremely
beneficial added-value flavor to the research effort.
Patients increasingly want to be part of the research pro-
cess. A recent strategic review of personal and public
involvement (PPI) in research (commissioned by the
National Institute for Health Research) emphasizes the
importance of a partnership model.44 In relation to
cancer, a survey of 811 patients revealed that> 90% indi-
cated a desire for their samples to be used in future
research, whereas a significant number of patients also
indicated that they wanted to participate in genomic test-
ing to allow for personalization of their treatment.45 As a
member of the European Patients’ Academy on Thera-
peutic Innovation (EUPATI),46 patient advocates from
the NICRCF promote a wider appreciation among
patients and the general public of the benefits and chal-
lenges of translational research and its application.
Although patient advocacy groups are particularly
active within the global cancer community, a PPI that
focuses primarily on research is unusual, particularly in
the European context. NICRCFmembers have a very par-
ticular experience of cancer, either as a cancer survivor, a
member of a family affected by cancer, or as a cancer care-
giver, and are committed to work with cancer researchers
and health care professionals to advance cancer research
activities and initiatives. In collaboration with Macmillan
Cancer Support, the NICRCF has piloted “Building
Research Partnerships in Northern Ireland,” a shared
learning activity between patients and health care profes-
sionals to support PPI in health and social research. Semi-
quantitative assessment of stage I (immediate evaluation)
has indicated> 95% efficacy in meeting participants’
needs, whereas stage II of the activity (transfer of learning
evaluation) is ongoing and its results are eagerly awaited.
As part of the S-CORT program, we also will attempt to
measure the value that patient advocacy brings to research
endeavors through a combination of surveys and qualita-
tive/semiquantitative assessments. The NICRCF com-
bines a pro-research advocacy agenda with a gatekeeper
function to ensure that the best, most ethically responsible
research is conducted that delivers both academic excel-
lence and patient relevance.
Education and Outreach: Innovative Doctoral
Training and Public Engagement
At a clinical level, a clinical academic training program,
mediated initially through fellowship training and short-
stay visits at the NCI and at NCI comprehensive cancer
centers as part of the All-Ireland-NCI Cancer Consor-
tium, underpinned the development of a cohort of indi-
viduals who have now assumed leadership roles in clinical
oncology, radiation oncology, and cancer clinical trials.
Specialist nursing expertise, particularly for cancer clinical
trials, also was developed through this mechanism.
Underpinning the framework described above are a
series of innovative educational and outreach activities.
The CCRCB doctoral training program in precision can-
cer medicine is providing students not only with the scien-
tific rigor and wet laboratory/bioinformatics skill sets with
which to conduct high-quality research, but also with the
business, entrepreneurial, innovation, and leadership
skills and acumen that will benefit them in their evolving
careers. Embedding bioindustry, the QUB’s Management
School, and the William J. Clinton Leadership Institute
within the educational program is ensuring the active
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transfer of relevant career-enhancing skills to the students.
A new aspect of the program is a recently established part-
nership with the NCI in the United States, allowing stu-
dents to perform research at the NCI as part of their PhD
studies. In this program, students first complete a Masters
by Research degree in precision cancer medicine, acquir-
ing not only the technical laboratory expertise but also the
innovation, business, and leadership skills to underpin
their future careers. Subsequent mentorship at the NCI as
part of the NIH Graduate Partnership Program will pro-
vide the students with a comprehensive research training
experience.
In pathology, we recognize the need for histopathol-
ogists to undergo molecular pathology training47 and
have developed a model for integrating specialist formal
training in molecular diagnostic/molecular pathology
within the existing 5-year histopathology training curricu-
lum.48 The recent CRUK Accelerator Award is underpin-
ning this innovative training program through a blended
learning Masters in the Molecular Pathology of Cancer
degree delivered by QUB for pathology trainees in Belfast,
the University of Southampton, University College Lon-
don, the University of Manchester, the University of
Newcastle, and the University of Leicester.
From a public engagement perspective, a vibrant
outreach program, supported through Cancer Research
UK and local charities and delivered by our Engagement
Committee, highlights our precision medicine approach
to personalized cancer care. Precision medicine has been a
significant theme at the inaugural NI Science Festival, the
CCRCB Open Day, and a recent Culture Night event.
These engagement events provide an essential opportunity
to inform and educate our stakeholders of the importance
of research to improving patient care and outcomes. At a
political level, we deliver engagement activities at the NI
Parliament buildings and regularly host government and
all-party committees at the CCRCB, thus both informing
politicians and policy makers of the importance of
research as well as highlighting the shared responsibilities
for all stakeholders to enhance the health and wealth of
NI’s citizens and societies.
IMPLEMENTING OUR VISION THROUGH
CONTINUED PATIENT-FOCUSED AND
RESEARCH-ENABLED INTERSECTORAL
PARTNERSHIP
As we have demonstrated in this article, the last 20 years
have witnessed significant advances in cancer care in NI,
leading to measureable improvements in patient out-
comes. Crucial to this transformation has been an ethos
that recognizes the primacy role of research in effecting
heath care change. Our model of a cross-sectoral partner-
ship that unites patients, scientists, health care professio-
nals, hospital trusts, bioindustry, and government
agencies can be truly transformative, empowering tripar-
tite clinical-academic-industry efforts that have already
yielded significant benefit and will continue to inform our
strategy and its implementation going forward. NI has a
population of only 1.85million individuals, with approxi-
mately 9000 new patients diagnosed with cancer each year
(excluding nonmelanoma skin cancer), but it is precisely
this compact size that works in our favor, allowing cancer
research and cancer services to be integrated, planned, and
delivered at the population level. A coordinated partner-
ship of all the key stakeholders with a clear unity of pur-
pose is beginning to catalyze a truly integrated research-
driven comprehensive cancer program, which we will con-
tinue to deliver through a linked health and social care
infrastructure that allows change to be effected across the
cancer continuum. As we move forward, the CCRCB
hopes to attract other biotechnology and pharma partners
to exploit the established discovery pipeline. Expanded
access will deliver significant health, wealth, and societal
benefits to NI and beyond, but also keep faith with the
challenge laid down by Senator Mitchell, to use “global
partnerships to relieve human suffering from cancer.”
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